Minerva cardiology and angiology最新文献_第5页

Atrial refractoriness early after transcatheter aortic valve implantation TAVI in patients with severe aortic stenosis and sinus rhythm. 严重主动脉瓣狭窄和窦性心律患者经导管主动脉瓣植入术（TAVI）术后早期的心房折返。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 DOI: 10.23736/S2724-5683.24.06540-2

Özcan Özdemir, Onur Yildirim

{"title":"Atrial refractoriness early after transcatheter aortic valve implantation TAVI in patients with severe aortic stenosis and sinus rhythm.","authors":"Özcan Özdemir, Onur Yildirim","doi":"10.23736/S2724-5683.24.06540-2","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06540-2","url":null,"abstract":"Background: Aortic valve stenosis (AS) is a common valvular heart disease, especially in the elderly, and is associated with a high prevalence of atrial fibrillation. Although the risk of atrial fibrillation is expected to decrease after the intervention, atrial fibrillation develops in many patients undergoing surgical or percutaneous transaortic valve implantation. We aimed to evaluate atrial refractoriness since it may play a key role in the occurrence of atrial fibrillation after transaortic valve implantation.Methods: Seventy-nine consecutive patients who underwent TAVI between October 2021 and May 2023 were enrolled in this trial. Sixty-seven patients underwent electrophysiology study before and after TAVI. We evaluated the changes in PA and AH intervals, as well as atrial effective refractory periods.Results: Besides the hemodynamic changes, atrial effective refractory periods increased, and atrial effective refractory period dispersion (39.8±21.6 vs. 31.1±18.0) decreased significantly after TAVI. The change in atrial effective refractory period dispersion after TAVI was correlated only with the changes in left ventricular end-diastolic pressure (r=0.77, P=0.001) and the changes in aortic gradient (r=0.4, P=0.001). The independent variables affecting the changes in atrial effective refractory period dispersion were basal pro-BNP levels, besides the changes in left ventricular end-diastolic pressure and aortic gradient after transaortic valve implantation.Conclusions: Our results show an acute improvement in atrial refractoriness after TAVI, though high atrial fibrillation rates are reported in the literature. The timing of aortic valve replacement is important, as irreversible maladaptive changes might have already developed by the time of intervention.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term benefits of drug-coated balloons for coronary artery revascularization. 药物涂层球囊用于冠状动脉血运重建的长期益处。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 Epub Date: 2023-12-21 DOI: 10.23736/S2724-5683.23.06425-6

Bernardo Cortese, Sara Malakouti, Waqas Mazhar, Florin Leontin Lazar, Amit Munjal, Yolande Ketchanji Mougang

{"title":"Long-term benefits of drug-coated balloons for coronary artery revascularization.","authors":"Bernardo Cortese, Sara Malakouti, Waqas Mazhar, Florin Leontin Lazar, Amit Munjal, Yolande Ketchanji Mougang","doi":"10.23736/S2724-5683.23.06425-6","DOIUrl":"10.23736/S2724-5683.23.06425-6","url":null,"abstract":"Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) represents the treatment of choice for the majority of patients with coronary artery disease. While currently available DES, in addition to physiological support, has failed to show the non-inferiority to coronary artery bypass grafting (CABG) in terms of cumulative incidence of clinical events over the short-term follow-up. Studies have also shown that DES is associated with an increased risk of target vessel revascularization compared to CABG after long-term follow-up. Drug-coated balloons (DCB) have been shown to provide clinically significant benefits in the management of in-stent restenosis and diffuse coronary artery disease, as well as small coronary artery lesions. The aim of this review was to describe the inherent technical limitations of DES and highlight the potential advantages of PCI with DCB for long-term outcomes and potentially demonstrate its non-inferiority to CABG. Currently, ongoing studies will provide more information and help to understand if a blended therapy of DCB+DES can match the performance of CABG in the need for revascularization in more complex patients.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"506-516"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138830478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet dysfunction caused by differentially expressed genes as key pathogenic mechanisms in COVID-19. 差异表达基因导致的血小板功能障碍是 COVID-19 的关键致病机制。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 Epub Date: 2024-05-27 DOI: 10.23736/S2724-5683.24.06501-3

Xiaoyong Tan, Xiaojun Gao, Huanhuan Zheng, Hui Yuan, Hong Liu, Qijun Ran, Mao Luo

{"title":"Platelet dysfunction caused by differentially expressed genes as key pathogenic mechanisms in COVID-19.","authors":"Xiaoyong Tan, Xiaojun Gao, Huanhuan Zheng, Hui Yuan, Hong Liu, Qijun Ran, Mao Luo","doi":"10.23736/S2724-5683.24.06501-3","DOIUrl":"10.23736/S2724-5683.24.06501-3","url":null,"abstract":"At the end of 2019, the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became prevalent worldwide, which brought a heavy medical burden and tremendous economic losses to the world population. In addition to the common clinical respiratory symptoms such as fever, cough and headache, patients with COVID-19 often have hematological diseases, especially platelet dysfunction. Platelet dysfunction usually leads to multiple organ dysfunction, which is closely related to patient severity or mortality. In addition, studies have confirmed significant changes in the gene expression profile of circulating platelets under SARS-CoV-2 infection, which will further lead to changes in platelet function. At the same time, studies have shown that platelets may absorb SARS-COV-2 mRNA independently of ACE2, which further emphasizes the importance of the stability of platelet function in defense against SARS-CoV-2 infection. This study reviewed the relationship between COVID-19 and platelet and SARS-CoV-2 damage to the circulatory system, and further analyzed the significantly differentially expressed mRNA in platelets after infection with SARS-CoV-2 on the basis of previous studies. The top eight hub genes were identified as NLRP3, MT-CO1, CD86, ICAM1, MT-CYB, CASP8, CXCL8 and CXCR4. Subsequently, the effects of SARS-CoV-2 infection on platelet transcript abnormalities and platelet dysfunction were further explored on the basis of 8 hub genes. Finally, the treatment measures of complications caused by platelet dysfunction in patients with COVID-19 were discussed in detail, so as to provide reference for the prevention, diagnosis and treatment of COVID-19.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"517-534"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on: "Is ChatGPT knowledgeable of acute coronary syndromes and pertinent European Society of Cardiology Guidelines?" 评论"ChatGPT是否了解急性冠状动脉综合征和相关的欧洲心脏病学会指南？

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 Epub Date: 2024-05-23 DOI: 10.23736/S2724-5683.24.06569-4

Hinpetch Daungsupawong, Viroj Wiwanitkit

引用次数: 0

Investigating hub genes in the relationship between septic cardiomyopathy and cuproptosis and potential Chinese herbal drug candidates with bioinformatic tools. 利用生物信息学工具研究脓毒性心肌病与杯状红细胞增多症关系中的枢纽基因及潜在的候选中药

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 Epub Date: 2024-05-27 DOI: 10.23736/S2724-5683.23.06476-1

Guangbao Pang, Kunlin Hu, Jianyu Ji, Bin Xiong, Lin Han, Jing Pang, Shulin Xiang

{"title":"Investigating hub genes in the relationship between septic cardiomyopathy and cuproptosis and potential Chinese herbal drug candidates with bioinformatic tools.","authors":"Guangbao Pang, Kunlin Hu, Jianyu Ji, Bin Xiong, Lin Han, Jing Pang, Shulin Xiang","doi":"10.23736/S2724-5683.23.06476-1","DOIUrl":"10.23736/S2724-5683.23.06476-1","url":null,"abstract":"Background: The aim of this study was using bioinformatic tools to identify hub genes in the relationship between septic cardiomyopathy (SCM) and cuproptosis and predict potential Chinese herbal drug candidates.Methods: SCM datasets were downloaded from the gene expression omnibus. Cuproptosis related genes were collected from a research published on Science in March, 2022. The expression profiles of genes related to cuproptosis in SCM were extracted. Differentially expressed genes (DEGs) were analyzed using R package limma. A single-sample gene set enrichment analysis was conducted to measure the correlation between DEGs and immune cell infiltration. Hub genes were screened out by random forest model. Finally, HERB database and COREMINE database were used to predict Chinese herbal drugs for hub genes and carry out molecular docking.Results: A total of 9 DEGs were identified. Cuproptosis differential genes PDHB, DLAT, DLD, FDX1, GCSH, LIAS were significantly correlated with one or more cells and their functions in immune infiltration. The random forest model screened pyruvate dehydrogenase E1 beta subunit (PDHB) as the hub gene. PDHB was negatively correlated with Plasmacytoid dendritic cell infiltration. Pyruvic acid, rhodioloside and adenosine were predicted with PDHB as the target, and all three components are able to bind to PDHB.Conclusions: Cuproptosis related gene PDHB is associated with the occurrence and immune infiltration of septic cardiomyopathy. Rhodioloside and other Chinese herbal drugs may play a role in the treatment of SCM by regulating the expression of PDHB.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"453-464"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dapagliflozin reverses combined postcapillary and precapillary pulmonary hypertension in a patient with advanced heart failure. 达帕格列净逆转了一名晚期心力衰竭患者的毛细血管后和毛细血管前合并肺动脉高压。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 Epub Date: 2024-05-16 DOI: 10.23736/S2724-5683.24.06592-X

Daniele Masarone, Luigi Falco, Dario Catapano, Rita Gravino, Fabio Valente

引用次数: 0

Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy. 降脂治疗对接受和不接受抗血小板治疗的患者血小板反应性的影响。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 Epub Date: 2023-10-23 DOI: 10.23736/S2724-5683.23.06411-6

Salvatore Giordano, Francesco Franchi, Fabiana Rollini, Tala Al Saleh, Ekin Uzunoglu, Francesco Costa, Dominick J Angiolillo, Luis Ortega-Paz

{"title":"Effect of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy.","authors":"Salvatore Giordano, Francesco Franchi, Fabiana Rollini, Tala Al Saleh, Ekin Uzunoglu, Francesco Costa, Dominick J Angiolillo, Luis Ortega-Paz","doi":"10.23736/S2724-5683.23.06411-6","DOIUrl":"10.23736/S2724-5683.23.06411-6","url":null,"abstract":"Circulating lipoproteins may interact with platelets, increasing platelet sensitivity to aggregating agonists and their tendency towards activation and thrombus formation. In particular, patients with hypercholesterolemia exhibit a higher degree of platelet reactivity compared to normolipidemic. Moreover, accruing evidence report that lipid-lowering therapies can reduce thrombus formation, particularly in the absence of concomitant antiplatelet therapy. However, the underlying biological mechanism(s) explaining these clinical observations are not completely understood. Baseline platelet reactivity and high on-treatment platelet reactivity while on antiplatelet therapy (e.g., aspirin and clopidogrel) are associated with poor clinical outcomes. Therefore, strategies to reduce baseline platelet reactivity or improve the pharmacodynamic profile of antiplatelet therapies are an unmet clinical need. The potential use of lipid-lowering therapies for optimizing platelet reactivity provides several advantages as there is strong evidence that reducing circulating lipoproteins can improve clinical outcomes, and they may avoid the need for potent antiplatelet therapies that, although more effective, are associated with increased bleeding risk. This review will provide a systematic overview of the effects of lipid-lowering therapy on platelet reactivity in patients treated with and without antiplatelet therapy. We will focus on the potential biological mechanism(s) of action and the effect of statins, ezetimibe, proprotein convertase subtilisin/kexin 9 inhibitors, omega-3 fatty acids, and recombinant high-density lipoprotein on platelet reactivity. Ultimately, we will assess the current gaps in the literature and future perspective in the field.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"489-505"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49691438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial fibrillation in transthyretin amyloidotic cardiomyopathy: prevalence and echocardiographic predictors. 经甲状腺素淀粉样变性心肌病中的心房颤动：发病率和超声心动图预测因素。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 DOI: 10.23736/S2724-5683.24.06566-9

María R Rodríguez, Ana Spaccavento, Mirta Diez, Diego Conde, Lucrecia M Burgos, Ivana M Seia, Alejandro Meretta, Adrian Baranchuk, Shyla Gupta, Juan P Costabel

{"title":"Atrial fibrillation in transthyretin amyloidotic cardiomyopathy: prevalence and echocardiographic predictors.","authors":"María R Rodríguez, Ana Spaccavento, Mirta Diez, Diego Conde, Lucrecia M Burgos, Ivana M Seia, Alejandro Meretta, Adrian Baranchuk, Shyla Gupta, Juan P Costabel","doi":"10.23736/S2724-5683.24.06566-9","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06566-9","url":null,"abstract":"Background: Conduction disorders and arrhythmias frequently accompany cardiac amyloidosis (CA), with atrial fibrillation (AF) being the most prevalent manifestation. The prevalence of AF varies across different types of CA, with transthyretin (TTR) type showing the highest prevalence upon diagnosis.Methods: A retrospective, observational analysis was conducted to evaluate the prevalence of AF and to identify echocardiographic predictors related to the development of AF in our population of patients with transthyretin cardiac amyloidosis (TTR-CA).Results: A total of 99 patients with TTR-CA were identified, with a median age of 82 (75-85) years, a median ejection fraction of 50% (43-60) and 97 of them wild type. At the time of cardiomyopathy diagnosis, 55% had AF, and during follow-up, 43% developed new AF. Among the latter group, there was a non-significant tendency to have a smaller diastolic diameter, lower left ventricular ejection fraction, increased septal thickness, higher pulmonary pressure, and lower tissue velocities, with statistical significance only found in the right ventricular S wave velocity: 8.5 cm/s (7.7-9) vs. 9.7 cm/s (8.4-10) (P=0.046).Conclusions: The high prevalence and incidence of AF in TTR-CA is demonstrated in our series. Doppler echocardiography might help to identify patients with signs of more advanced cardiomyopathy, such as lower right ventricle tissue velocity, who might be at higher risk of developing AF and gain the benefit of prompt diagnosis and treatment.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current approaches to preventing heart failure readmissions and decompensated disease. 目前预防心力衰竭再入院和失代偿疾病的方法。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 Epub Date: 2023-07-05 DOI: 10.23736/S2724-5683.23.06284-1

Matthew Mace, Niklas Lidströmer

{"title":"Current approaches to preventing heart failure readmissions and decompensated disease.","authors":"Matthew Mace, Niklas Lidströmer","doi":"10.23736/S2724-5683.23.06284-1","DOIUrl":"10.23736/S2724-5683.23.06284-1","url":null,"abstract":"Heart failure is a resource-intensive condition to manage and typically involves a multi-disciplinary and multi-modality approach leading to an expensive treatment paradigm. It is worth noting that hospital admissions constitute over 80% of heart failure management costs. In the past two decades, healthcare systems have developed new ways of following patients remotely to prevent them from being readmitted to the hospital. However, despite these efforts, hospital admissions have still increased. Many successful readmission reduction programs prioritize education and self-care to increase patients' awareness of their disease and promote lasting lifestyle changes. While socioeconomic factors impact success, interventions tend to be effective when medication adherence and guideline-directed medical therapy are emphasized. Monitoring intracardiac pressure can improve resource allocation efficiency and has demonstrated significant reductions in readmissions with improved quality of life in outpatient and remote settings. Data from several studies focused on remote monitoring devices strongly suggest that understanding congestion using physiological biomarkers is an effective management strategy. Since most cases of heart failure are first presented in acute hospitalization settings, immediate access to intracardiac pressure for treatment and decision-making purposes could result in substantial management improvements. However, a notable technology gap needs to be addressed to enable this at a low cost with less reliability on scarce specialist care resources. Contemporary evidence is conclusive that direct hemodynamic are the vital signs in heart failure with the highest clinical utility. Therefore, future ability to obtain these insights reliably using non-invasive methods will be a paradigm-changing technology.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"535-543"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-1 blockade in cardiovascular disease: an appraisal of the evidence across different inflammatory paradigms. 阻断 IL-1 治疗心血管疾病：不同炎症范例的证据评估。

IF 1.4 4区医学

Minerva cardiology and angiology Pub Date : 2024-10-01 Epub Date: 2023-09-13 DOI: 10.23736/S2724-5683.23.06390-1

Aldo Bonaventura, Francesco Moroni, Michele Golino, Marco G Del Buono, Alessandra Vecchié, Nicola Potere, Antonio Abbate

{"title":"IL-1 blockade in cardiovascular disease: an appraisal of the evidence across different inflammatory paradigms.","authors":"Aldo Bonaventura, Francesco Moroni, Michele Golino, Marco G Del Buono, Alessandra Vecchié, Nicola Potere, Antonio Abbate","doi":"10.23736/S2724-5683.23.06390-1","DOIUrl":"10.23736/S2724-5683.23.06390-1","url":null,"abstract":"Pre-clinical and clinical studies suggest a role for inflammation in the pathophysiology of cardiovascular (CV) diseases. The NLRP3 (NACHT, leucine-rich repeat, and pyrin domain-containing protein 3) inflammasome is activated during tissue injury and releases interleukin-1β (IL-1β). We describe three paradigms in which the NLRP3 inflammasome and IL-1β contribute to CV diseases. During acute myocardial infarction (AMI), necrotic cell debris, including IL-1α, induce NLRP3 inflammasome activation and further damage the myocardium contributing to heart failure (HF) (acute injury paradigm). In chronic HF, IL-1β is induced by persistent myocardial overload and injury, neurohumoral activation and systemic comorbidities favoring infiltration and activation of immune cells into the myocardium, microvascular inflammation, and a pro-fibrotic response (chronic inflammation paradigm). In recurrent pericarditis, an autoinflammatory response triggered by cell injury and maintained by the NLRP3 inflammasome/IL-1β axis is present (autoinflammatory disease paradigm). Anakinra, recombinant IL-1 receptor antagonist, inhibits the acute inflammatory response in patients with ST elevation myocardial infarction (STEMI) and acute HF. Canakinumab, IL-1β antibody, blunts systemic inflammation and prevents complications of atherosclerosis in stable patients with prior AMI. In chronic HF, anakinra reduces systemic inflammation and improves cardiorespiratory fitness. In recurrent pericarditis, anakinra and rilonacept, a soluble IL-1 receptor chimeric fusion protein blocking IL-1α and IL-1β, treat and prevent acute flares. In conclusion, the NLRP3 inflammasome and IL-1 contribute to the pathophysiology of CV diseases, and IL-1 blockade is beneficial with different roles in the acute injury, chronic inflammation and autoinflammatory disease paradigms. Further research is needed to guide the optimal use of IL-1 blockers in clinical practice.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":"477-488"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10235511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0